Related Experiment Video

Updated: Apr 24, 2026

Evaluating the Effectiveness of Cancer Drug Sensitization In Vitro and In Vivo
09:19

Evaluating the Effectiveness of Cancer Drug Sensitization In Vitro and In Vivo

Published on: February 6, 2015

8.3K

Structure-guided optimization of SLC1A1/EAAT3-selective inhibitors targeting renal cancer metabolism

Pooneh Koochaki1, Biao Qiu2,3, Jesse A Coker4,5

  • 1Department of Cancer Sciences, Cleveland Clinic Research, Cleveland, OH, USA.

The EMBO Journal
|April 22, 2026
PubMed

Insights

Researchers elucidated how compound 3e targets the SLC1A1 transporter, crucial for renal cell carcinomas (RCCs). This discovery enables the development of new cancer therapies by blocking SLC1A1 activity.

Area of Science:

  • Biochemistry
  • Molecular Biology
  • Structural Biology

Background:

  • Renal cell carcinoma (RCC) relies on the SLC1A1/EAAT3 transporter.
  • Targeting SLC1A1 pharmacologically presents significant challenges.

Purpose of the Study:

  • Determine the cryo-EM structure of human SLC1A1 bound to the inhibitor compound 3e.
  • Elucidate the mechanism of action for SLC1A1-selective inhibitors.
  • Guide the design of novel SLC1A1 inhibitors for RCC treatment.

Main Methods:

  • Cryo-electron microscopy (cryo-EM) to determine the structure of human SLC1A1.
  • Biochemical assays to assess inhibitor binding and transport inhibition.
  • Cell-based assays to evaluate cytotoxicity in RCC cells.

Main Results:

  • Compound 3e binds to an allosteric pocket in SLC1A1, accessible in the apo state.
  • 3e inhibits sodium and substrate binding by preventing essential elevator-like movements.
  • Mutations in the 3e binding pocket confirm on-target activity and selectivity.
  • New derivatives, PBJ1 and PBJ2, show enhanced cytotoxicity against RCC cells.

Conclusions:

  • The structural insights into SLC1A1-3e binding provide a mechanism for inhibitor action.
  • Compound 3e and its derivatives represent promising therapeutic agents for RCC.
  • Targeting SLC1A1 offers a viable strategy for novel RCC treatment approaches.

More Related Videos

Technical Aspect of the Automated Synthesis and Real-Time Kinetic Evaluation of [11C]SNAP-794109:50

Technical Aspect of the Automated Synthesis and Real-Time Kinetic Evaluation of [11C]SNAP-7941

Published on: April 28, 2019

9.0K
Pooled shRNA Library Screening to Identify Factors that Modulate a Drug Resistance Phenotype14:51

Pooled shRNA Library Screening to Identify Factors that Modulate a Drug Resistance Phenotype

Published on: June 17, 2022

2.7K

Related Concept Videos

Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase01:11

Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase

Genetic polymorphisms in drug targets have emerged as critical determinants of interindividual variability in drug response and toxicity. Pharmacogenomic investigations increasingly focus on identifying these variations to personalize and optimize therapeutic interventions. A drug target may be a receptor, enzyme, or signaling protein involved in pharmacologic responses or disease-related pathways. While early pharmacogenetic studies focused primarily on drug metabolism, current research...
80
Pharmacogenetics of Phase II Enzymes: N-acetyltransferase, Thiopurine S-methyltransferase, UDP-glucuronosyltransferase01:27

Pharmacogenetics of Phase II Enzymes: N-acetyltransferase, Thiopurine S-methyltransferase, UDP-glucuronosyltransferase

Phase II biotransformation reactions are essential for detoxifying and eliminating xenobiotics, including many pharmaceutical compounds. These reactions typically involve conjugation, the covalent attachment of polar endogenous groups such as glucuronic acid, sulfate, methyl, or acetyl moieties to functional groups introduced during Phase I metabolism. The resulting conjugates are more water-soluble, enabling efficient renal or biliary excretion.The major classes of Phase II enzymes include...
93
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
7.0K
Pharmacogenetics of Drug Transporters: P-Glycoprotein and Solute Carrier Transporters01:16

Pharmacogenetics of Drug Transporters: P-Glycoprotein and Solute Carrier Transporters

The pharmacogenetics of drug transporters is increasingly recognized as a critical factor influencing interindividual variability in drug absorption, distribution, and elimination. These membrane-bound proteins regulate drugs' movement across cellular barriers by actively pumping them out (efflux) or facilitating their uptake (influx). Among the major transporter families, ATP-binding cassette (ABC) and solute carrier (SLC) transporters play particularly prominent roles. Genetic polymorphisms...
186
Combination Therapies and Personalized Medicine02:50

Combination Therapies and Personalized Medicine

Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
4.9K
Structure-Activity Relationships and Drug Design01:28

Structure-Activity Relationships and Drug Design

Drug design is a dynamic field that involves discovering and developing new medications based on specific biological targets. This process heavily relies on structure-activity relationships (SAR) and quantitative structure-activity relationships (QSAR) to guide the design and optimization of efficient drugs.
SAR studies the intricate relationship between a drug's chemical structure and biological activity. It focuses on understanding how modifications to a drug's structure can influence...
1.8K